<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
New fill/finish partnership with BioConnection provides end-to-end drug product development under 1 contract!   Read the press release

2 min read

ASGCT Annual Meeting, May 7-11

ASGCT Annual Meeting, May 7-11

Booth: #527

Date: May 7-11, 2024

Location: Baltimore Convention Center - Get directions

Event website: https://annualmeeting.asgct.org/ 



Join us May 8, 13:30 - 14:00 Giuliana Vallanti, our Vice President of Development and Global R&D, will be presenting at the symposia: "Designing Process, Analytical Validation, and Characterization Studies for EU & FDA Approval"


  • Development and Qualification of a Quality Control Panel for the Characterization of Recombinant Adeno Associated Viral Vectors (Poster #891) presented by Francesca Rossetti on Wednesday, May 8 from 12:00-19:00 in Exhibit Hall
  • Optimization of Automated Selection and Lentiviral Vector Mediated Transduction of MSCs (Poster #1380) presented by Giuliana Vallanti Thursday, May 9 from 12:00-19:00 in Exhibit Hall
  • Examining the Development Challenges of AAV and LVV Manufacturing Processes: A Comparative Perspective (Poster #1850) presented by Giuliana Vallanti on Friday, May 10 from 12:00-19:00 in Exhibit Hall


Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below, or email one of our attending representatives to set up a meeting.


You can also reach out directly to our experts attending the show

Giuliana Vallanti
VP, Development & Global R&D C&G
Email  me
Luca Alberici
Site Head of Milan Facility
Email  me
Francesca Rossetti
Analytical Method Development Director
Email  me
Raghu Malapaka, PhD
Sr. Director, Business Development
Email  me
Paul DiCandeloro
Sr. Director, Business Development
Email  me

Explore our AAV & LVV Platforms

BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.  

Our new templated adeno-associated viral vector platform.

 Learn about Bravo

Our new templated lentiviral vector platform.

Learn about our cell and gene therapy services 

Cell Therapy Production and Manufacturing

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.  

Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting. 

Cell therapy offering 

Viral Vector Production and Manufacturing 

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products. 

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Viral vector services 

Plasmid DNA (pDNA) Materials 

To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing. 

Plasmid offering


Fill out the form below to request a meeting during the event